I don’t know, Orlando. But, I think you nailed it- “not warranted yet.” If I were a CEO making an acquisition and the company I was acquiring made such a move, I’d say no way or the deal is over. It also goes against what we see with Gnbt management. Glutinous ways left with Gluskin.

Excellagen is a bit like Oral-lyn. You can understand positive prospects, but for whatever reason no actual success or revenue. Yes, that could change with a better team, but prove something first. Gnbt already paid a hefty hefty premium vs. what Olaregen just recently paid for partial rights for Excellagen. That already takes a leap of faith for Gnbt shareholders, never mind raises and bonuses for Olaregen execs just as the acquisition occurs.